RxDoctor Payments Data

Lauren Powell, NP

Family · Chapin, SCNPI 1588078042

Payments from drug & device makers

$1,318in general payments, 2019–2025

Across 65 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$196
  • Abbott$170
  • Novo Nordisk$145
  • Amgen$109
  • Pfizer$104
  • AstraZeneca$94
  • plus $500 from 13 others

What the payments were for

  • Food & beverage$1,30499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,318 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$127,150
Medicare patients
254
Services billed
5,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$125,591
FarxigaDapagliflozin Propanediol79$75,937
EliquisApixaban71$66,552
MounjaroTirzepatide61$63,679
JardianceEmpagliflozin61$61,011
TrulicityDulaglutide38$35,519
Tresiba Flextouch U-200Insulin Degludec38$33,570
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$21,962
Synjardy XrEmpagliflozin/Metformin Hcl38$20,964
Xigduo XrDapaglifloz Propaned/Metformin20$20,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,947
XareltoRivaroxaban18$14,328
MyrbetriqMirabegron25$13,278
Icosapent Ethyl22$5,647
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$145$125,591109 claims
Lilly USA, LLCMounjaro, Trulicity$83$99,19899 claims
AstraZenecaFarxiga, Bevespi Aerosphere$94$80,64690 claims
PfizerEliquis$104$66,55271 claims
Astellas Pharma US IncMyrbetriq$17$13,27825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Chapin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →